Fisetin-dose 2
Phase 2Small molecule
Fisetin-dose 2 is one of 38 small molecule programs targeting Sepsis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
112 competitors in Sepsis
#DrugCompanyPhaseTrials
1N-Acetylcysteine (NAC) Treatment
TThe First Affiliated Hospital of Soochow University
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 2
Heparin Sodium
BBaxter Healthcare Corporation
Phase 2
Actimmune
HHorizon Therapeutics Ireland DAC
Phase 2
Nafamostat Mesylate
EEnsysce Biosciences
Phase 3
Hydrocortisone Administration
UUniversity of Virginia
Phase 3
Sivelestat
Eli LillyPhase 2
Simdax
Orion Corporation, Orion PharmaPreclinical
Zyvox
PfizerPreclinical
Zemplar
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fisetin-dose 2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Minnesota